The original study to demonstrate that CHEK2 was associated with increased female breast cancer risk was based on the truncating European founder GPV, c.1100del (p.Thr367fs), herein referred to as “1100delC”, showing the risk to be around two-fold [13], with subsequent studies confirming this original estimate [7,14]. Here, CHEK2 is linked to breast carcinoma.